Leoni, C.* ; Bataclan, M.* ; Ito-Kureha, T.* ; Heissmeyer, V. ; Monticelli, S.*
The mRNA methyltransferase Mettl3 modulates cytokine mRNA stability and limits functional responses in mast cells.
Nat. Commun. 14:3862 (2023)
Mast cells are central players in allergy and asthma, and their dysregulated responses lead to reduced quality of life and life-threatening conditions such as anaphylaxis. The RNA modification N6-methyladenosine (m6A) has a prominent impact on immune cell functions, but its role in mast cells remains unexplored. Here, by optimizing tools to genetically manipulate primary mast cells, we reveal that the m6A mRNA methyltransferase complex modulates mast cell proliferation and survival. Depletion of the catalytic component Mettl3 exacerbates effector functions in response to IgE and antigen complexes, both in vitro and in vivo. Mechanistically, deletion of Mettl3 or Mettl14, another component of the methyltransferase complex, lead to the enhanced expression of inflammatory cytokines. By focusing on one of the most affected mRNAs, namely the one encoding the cytokine IL-13, we find that it is methylated in activated mast cells, and that Mettl3 affects its transcript stability in an enzymatic activity-dependent manner, requiring consensus m6A sites in the Il13 3’-untranslated region. Overall, we reveal that the m6A machinery is essential in mast cells to sustain growth and to restrain inflammatory responses.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Methylation; M(6)a; Complex; Proteins; Subunit; Family; Model; Wtap
Keywords plus
Language
english
Publication Year
2023
Prepublished in Year
0
HGF-reported in Year
2023
ISSN (print) / ISBN
2041-1723
e-ISSN
2041-1723
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 14,
Issue: 1,
Pages: ,
Article Number: 3862
Supplement: ,
Series
Publisher
Nature Publishing Group
Publishing Place
London
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Immune Response and Infection
PSP Element(s)
G-501712-001
Grants
Swiss National Science Foundation (SNF)
Swiss National Science Foundation
Fondazione Aldo e Cele
German Research Foundation
Copyright
Erfassungsdatum
2023-10-18